{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T20:52:52Z","timestamp":1792788772403,"version":"4.5.0"},"reference-count":36,"publisher":"Public Library of Science (PLoS)","issue":"7","license":[{"start":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T00:00:00Z","timestamp":1625788800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pfizer France"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Context<\/jats:title>\n                    <jats:p>Sickle cell disease (SCD) is a severe hematological disorder. The most common acute complication of SCD is vaso-occlusive crisis (VOC), but SCD is a systemic disease potentially involving all organs. SCD prevalence estimates rely mostly on extrapolations from incidence-based newborn screening programs, although recent improvements in survival may have led to an increase in prevalence, and immigration could account for a substantial number of prevalent patients in Europe. The primary objective of this study was to estimate SCD prevalence in France.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      A cross-sectional observational study was conducted using a representative sample of national health insurance data. SCD patients followed up in France between 2006 and 2011 were captured through hydroxyurea reimbursement and with the International Classification of Diseases (ICD-10) SCD specific code D570.1.2, excluding code D573 (which corresponds to sickle cell trait (SCT)). Nevertheless, we assumed that ICD-10 diagnosis coding for inpatient stays could be imperfect, with the possibility of SCT being miscoded as SCD. Therefore, prevalence was analyzed in two groups of patients [with at least\n                      <jats:bold>one (G1) or two (G2) inpatient stay<\/jats:bold>\n                      ] based on the number of SCD-related inpatient stays in the six-year study period, assuming that SCT patients are rarely rehospitalized compared to SCD. The prevalence of SCD in the sample, which was considered to be representative of the French population, was then extrapolated to the general population. The rate of vaso-occlusive crisis (VOC) events was estimated based on hospitalizations, emergencies, opioid reimbursements, transfusions, and sick leave.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Based on the number of patients identified for G1 and G2, the 2016 French prevalence was estimated to be between 48.6 per 100,000 (G1) or 32,400 patients and 29.7 per 100,000 (G2) or 19,800 patients. An average of 1.51 VOC events per year were identified, with an increase frequency of 15 to 24 years of age. The average annual number of hospitalizations was between 0.70 (G1) and 1.11 (G2) per patient. Intensive care was observed in 7.6% of VOC-related hospitalizations. Fewer than 34% of SCD patients in our sample received hydroxyurea at any point in their follow-up. The annual average cost of SCD care is \u20ac5,528.70 (G1) to \u20ac6,643.80 (G2), with most costs arising from hospitalization and lab testing.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study estimates SCD prevalence in France at between 19,800 and 32,400 patients in 2016, higher than previously published. This study highlights the significant disease burden associated with vaso-occlusive events.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0253986","type":"journal-article","created":{"date-parts":[[2021,7,9]],"date-time":"2021-07-09T14:03:47Z","timestamp":1625839427000},"page":"e0253986","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":65,"title":["Epidemiology and disease burden of sickle cell disease in France: A descriptive study based on a French nationwide claim database"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4930-6767","authenticated-orcid":true,"given":"Henri","family":"Leleu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean Benoit","family":"Arlet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anoosha","family":"Habibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryse","family":"Etienne-Julan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mehdi","family":"Khellaf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yolande","family":"Adjibi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"France","family":"Pirenne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marine","family":"Pitel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Granghaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cynthia","family":"Sinniah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariane","family":"De Montalembert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fr\u00e9d\u00e9ric","family":"Galacteros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,7,9]]},"reference":[{"issue":"10091","key":"pone.0253986.ref001","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/S0140-6736(17)30193-9","article-title":"Sickle cell disease","volume":"390","author":"R.E. Ware","year":"2017","journal-title":"The Lancet"},{"issue":"10","key":"pone.0253986.ref002","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1001\/jama.2014.10517","article-title":"Management of Sickle Cell Disease: Summary of the 2014 Evidence-Based Report by Expert Panel Members","volume":"312","author":"B.P. Yawn","year":"2014","journal-title":"JAMA"},{"issue":"1","key":"pone.0253986.ref003","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1002\/ajh.21550","article-title":"Definitions of the phenotypic manifestations of sickle cell disease","volume":"85","author":"S.K. Ballas","year":"2010","journal-title":"Am J Hematol"},{"issue":"5 Suppl 1","key":"pone.0253986.ref004","first-page":"5S3","article-title":"French guidelines for the management of adult sickle cell disease: 2015 update","volume":"36","author":"A. Habibi","year":"2015","journal-title":"Rev Med Interne"},{"issue":"6","key":"pone.0253986.ref005","doi-asserted-by":"crossref","DOI":"10.1097\/01.AOG.0000127433.23611.54","article-title":"Outcome of Pregnancy in Homozygous Sickle Cell Disease","volume":"103","author":"G.R. Serjeant","year":"2004","journal-title":"Obstetrics & Gynecology"},{"issue":"27\u201328","key":"pone.0253986.ref006","first-page":"317","article-title":"\u00c9tudes descriptives de la mortalit\u00e9 et des hospitalisations li\u00e9es \u00e0 la dr\u00e9panocytose en France","author":"F. Suzan","year":"2012","journal-title":"Bulletin \u00e9pid\u00e9miologique hebdomadaire"},{"issue":"3","key":"pone.0253986.ref007","doi-asserted-by":"crossref","DOI":"10.1097\/MOH.0b013e328351c35f","article-title":"Clinical management of adult sickle-cell disease","volume":"19","author":"P. Bartolucci","year":"2012","journal-title":"Current Opinion in Hematology"},{"issue":"12","key":"pone.0253986.ref008","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1016\/j.mayocp.2018.08.001","article-title":"Advances in the Treatment of Sickle Cell Disease","volume":"93","author":"S. Kapoor","year":"2018","journal-title":"Mayo Clin Proc"},{"issue":"2","key":"pone.0253986.ref009","first-page":"73","article-title":"Advances in sickle cell disease treatments: Towards targeted therapies","volume":"41","author":"J.B. Arlet","year":"2020","journal-title":"Rev Med Interne"},{"issue":"27\u201328","key":"pone.0253986.ref010","first-page":"313","article-title":"Le d\u00e9pistage n\u00e9onatal de la dr\u00e9panocytose en France","author":"J. Bardakdjian Michau","year":"2012","journal-title":"Bulletin \u00e9pid\u00e9miologique hebdomadaire"},{"issue":"1","key":"pone.0253986.ref011","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1080\/00365510601046557","article-title":"Epidemiology of haemoglobin disorders in Europe: an overview","volume":"67","author":"B. Modell","year":"2007","journal-title":"Scand J Clin Lab Invest"},{"issue":"9","key":"pone.0253986.ref012","first-page":"1191","article-title":"La dr\u00e9panocytose en France en 2006: acquis et d\u00e9fis","volume":"13","author":"M. de Montalembert","year":"2006","journal-title":"Archives de P\u00e9diatrie"},{"issue":"12","key":"pone.0253986.ref013","doi-asserted-by":"crossref","DOI":"10.3390\/jcm8122173","article-title":"Comparison between Adult Patients with Sickle Cell Disease of Sub-Saharan African Origin Born in Metropolitan France and in Sub-Saharan Africa","volume":"8","author":"V. Honsel","year":"2019","journal-title":"J Clin Med"},{"issue":"23","key":"pone.0253986.ref014","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJM199406093302303","article-title":"Mortality In Sickle Cell Disease -- Life Expectancy and Risk Factors for Early Death","volume":"330","author":"O.S. Platt","year":"1994","journal-title":"New England Journal of Medicine"},{"issue":"8","key":"pone.0253986.ref015","first-page":"142","article-title":"Mortalit\u00e9 li\u00e9e \u00e0 la dr\u00e9panocytose en France: \u00c2ge de d\u00e9c\u00e8s et causes associ\u00e9es (1979\u20132010)","volume":"2015","author":"E. Gomes","year":"2015","journal-title":"Bulletin \u00e9pid\u00e9miologique hebdomadaire"},{"issue":"17","key":"pone.0253986.ref016","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.1182\/blood-2009-07-233700","article-title":"Improved survival of children and adolescents with sickle cell disease","volume":"115","author":"C.T. Quinn","year":"2010","journal-title":"Blood"},{"issue":"4","key":"pone.0253986.ref017","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1016\/j.respe.2010.04.005","article-title":"French national health insurance information system and the permanent beneficiaries sample","volume":"58","author":"P. Tuppin","year":"2010","journal-title":"Revue d\u2019epidemiologie et de sante publique"},{"issue":"1","key":"pone.0253986.ref018","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1111\/bjh.14040","article-title":"Morbidity and mortality of sickle cell disease patients starting intermittent haemodialysis: a comparative cohort study with non- Sickle dialysis patients","volume":"174","author":"L. Nielsen","year":"2016","journal-title":"Br J Haematol"},{"issue":"4","key":"pone.0253986.ref019","doi-asserted-by":"crossref","first-page":"39","DOI":"10.29245\/2572-9411\/2017\/4.1124","article-title":"The accuracy of hospital ICD-9-CM codes for determining Sickle Cell Disease genotype","volume":"2","author":"A.B. Snyder","year":"2017","journal-title":"J Rare Dis Res Treat"},{"issue":"5 Suppl","key":"pone.0253986.ref020","doi-asserted-by":"crossref","first-page":"S61","DOI":"10.1016\/j.acap.2014.02.008","article-title":"Identifying sickle cell disease cases using administrative claims","volume":"14","author":"S. Reeves","year":"2014","journal-title":"Acad Pediatr"},{"issue":"2","key":"pone.0253986.ref021","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1182\/blood.V86.2.776.bloodjournal862776","article-title":"Clinical events in the first decade in a cohort of infants with sickle cell disease. Cooperative Study of Sickle Cell Disease","volume":"86","author":"F.M. Gill","year":"1995","journal-title":"Blood"},{"issue":"10","key":"pone.0253986.ref022","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/jcm8101594","article-title":"Evaluation of Outcomes and Quality of Care in Children with Sickle Cell Disease Diagnosed by Newborn Screening: A Real-World Nation-Wide Study in France","volume":"8","author":"V. Brousse","year":"2019","journal-title":"Journal of Clinical Medicine"},{"issue":"5","key":"pone.0253986.ref023","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1111\/bjh.12700","article-title":"Transition from paediatric to adult care for patients with sickle cell disease","volume":"164","author":"t.F.R.C.f.S.C. Disease","year":"2014","journal-title":"British Journal of Haematology"},{"issue":"1","key":"pone.0253986.ref024","doi-asserted-by":"crossref","first-page":"e27463","DOI":"10.1002\/pbc.27463","article-title":"Transition to adult care in sickle cell disease: A longitudinal study of clinical characteristics and disease severity","volume":"66","author":"M. Kayle","year":"2019","journal-title":"Pediatric Blood & Cancer"},{"key":"pone.0253986.ref025","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1097\/01.HS9.0000561236.27342.05","article-title":"MORTALITY IN CHILDREN WITH SICKLE CELL DISEASE IN METROPOLITAN FRANCE FROM 2000 TO 2015: PF738","volume":"3","author":"V. Brousse","year":"2019","journal-title":"HemaSphere"},{"issue":"Supplement_1","key":"pone.0253986.ref026","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1182\/blood-2019-131304","article-title":"Causes of Death in 198 Sickle Cell Adult Patients: Old and New Trends","volume":"134","author":"A. Habibi","year":"2019","journal-title":"Blood"},{"issue":"7","key":"pone.0253986.ref027","doi-asserted-by":"crossref","first-page":"865","DOI":"10.3324\/haematol.11474","article-title":"Sickle cell disease as a paradigm of immigration hematology: new challenges for hematologists in Europe","volume":"92","author":"I. Roberts","year":"2007","journal-title":"Haematologica"},{"key":"pone.0253986.ref028","unstructured":"Boisgu\u00e9rin, B. and B. Haury, Les b\u00e9n\u00e9ficiaires de l\u2019AME en contact avec le syst\u00e8me de soins. 2008."},{"issue":"3","key":"pone.0253986.ref029","doi-asserted-by":"crossref","first-page":"e291","DOI":"10.1093\/pubmed\/fdx172","article-title":"How many people have sickle cell disease in the UK?","volume":"40","author":"E. Dormandy","year":"2018","journal-title":"J Public Health (Oxf)"},{"issue":"11","key":"pone.0253986.ref030","doi-asserted-by":"crossref","first-page":"e79923","DOI":"10.1371\/journal.pone.0079923","article-title":"Severe painful vaso-occlusive crises and mortality in a contemporary adult sickle cell anemia cohort study","volume":"8","author":"D.S. Darbari","year":"2013","journal-title":"PloS one"},{"issue":"2","key":"pone.0253986.ref031","doi-asserted-by":"crossref","first-page":"94","DOI":"10.7326\/0003-4819-148-2-200801150-00004","article-title":"Daily assessment of pain in adults with sickle cell disease","volume":"148","author":"W.R. Smith","year":"2008","journal-title":"Ann Intern Med"},{"issue":"1","key":"pone.0253986.ref032","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1002\/ajh.20336","article-title":"Hospital readmission for adult acute sickle cell painful episodes: frequency, etiology, and prognostic significance","volume":"79","author":"S.K. Ballas","year":"2005","journal-title":"Am J Hematol"},{"issue":"4","key":"pone.0253986.ref033","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.jpainsymman.2004.07.006","article-title":"Are there phases to the vaso-occlusive painful episode in sickle cell disease?","volume":"29","author":"E. Jacob","year":"2005","journal-title":"J Pain Symptom Manage"},{"issue":"3","key":"pone.0253986.ref034","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1034\/j.1600-0609.2000.90210.x","article-title":"Acute clinical events in 299 homozygous sickle cell patients living in France","volume":"65","author":"M.G. Neonato","year":"2000","journal-title":"European Journal of Haematology"},{"issue":"1","key":"pone.0253986.ref035","doi-asserted-by":"crossref","first-page":"e26758","DOI":"10.1002\/pbc.26758","article-title":"An analysis of inpatient pediatric sickle cell disease: Incidence, costs, and outcomes","volume":"65","author":"L.M. Bou-Maroun","year":"2018","journal-title":"Pediatric Blood & Cancer"},{"key":"pone.0253986.ref036","unstructured":"L\u2019Assurance Maladie, Cartographies des pathologies et des d\u00e9penses, D\u00e9penses rembours\u00e9es affect\u00e9es aux pathologies en 2018. https:\/\/www.ameli.fr\/l-assurance-maladie\/statistiques-et-publications\/etudes-en-sante-publique\/cartographie-des-pathologies-et-des-depenses\/depenses-remboursees-affectees-a-chaque-pathologie.php"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,3]],"date-time":"2024-09-03T16:47:35Z","timestamp":1725382055000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0253986"}},"subtitle":[],"editor":[{"given":"Ambroise","family":"Wonkam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,7,9]]},"references-count":36,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2021,7,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0253986","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,7,9]]}}}